Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU.

The European respiratory journal·1998
Same author

Respiratory mechanics in ventilated COPD patients: forced oscillation versus occlusion techniques.

The European respiratory journal·1998
Same author

Subclavian vascular access stenosis in dialysis patients: natural history and risk factors.

Journal of the American Society of Nephrology : JASN·1998
Same author

ATP-sensitive K+ channel blocker glibenclamide and diaphragm fatigue during normoxia and hypoxia.

Journal of applied physiology (Bethesda, Md. : 1985)·1998
Same author

Prognostic significance of p53 gene mutations in squamous cell carcinoma of the lung.

Oncology reports·1998
Same author

[Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].

Revista de neurologia·1998

Related Experiment Video

Updated: Jul 17, 2026

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
12:27

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice

Published on: April 2, 2014

Lung inflammatory response in pneumonia

C Montón1, A Torres

  • 1Departament de Medicina, Institut d'Investigations Biomédiques August Pi i Sumyer, Hospital Clínic, Barcelona, Spain.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|June 20, 1998
PubMed
Summary

Alveolar macrophages initiate pneumonia defense, recruiting neutrophils. Excessive inflammation, marked by cytokines like IL-6, can be harmful, but IL-10 offers balance.

Area of Science:

  • Immunology
  • Pulmonology
  • Critical Care Medicine

Background:

  • Alveolar macrophages (AMs) are the primary responders to lower airway bacterial infections.
  • Recruitment of polymorphonuclear neutrophils (PMNs) is essential when AMs are overwhelmed, mediated by cytokines like TNF-alpha, IL-1beta, IL-6, and IL-8.
  • Excessive inflammation can lead to sepsis and multi-organ failure, while IL-10 helps attenuate these responses.

Purpose of the Study:

  • To analyze the inflammatory response in pneumonia, focusing on cytokine profiles and their clinical implications.
  • To investigate the compartmentalization of inflammatory mediators in the lung during pneumonia.
  • To explore the potential of inflammatory markers as prognostic indices and therapeutic targets.

Main Methods:

  • Bronchoalveolar lavage was used to measure inflammatory mediators, including TNF-alpha, IL-1beta, IL-6, and IL-8, in human pneumonia patients.

More Related Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Experiment Videos

Last Updated: Jul 17, 2026

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
12:27

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice

Published on: April 2, 2014

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

  • C-reactive protein (CRP) levels were assessed as a marker related to IL-6 activity.
  • The relationship between bacterial load and inflammatory response intensity was examined.

    • Main Results:

    • Pneumonia's inflammatory response is largely compartmentalized, with IL-6 serving as a general inflammation marker.
    • IL-6 correlates with C-reactive protein, a measurable indicator of systemic inflammation.
    • Cytokine levels may serve as prognostic indices, though a direct link between bacterial burden and inflammation intensity was not found.
    • Granulocyte colony-stimulating factor (G-CSF) shows therapeutic promise but requires further clinical investigation.

    Conclusions:

    • Understanding pneumonia's inflammatory dynamics, particularly cytokine profiles, is crucial for patient management.
    • Targeting the balance between beneficial and deleterious inflammation is a key future therapeutic goal.
    • Measuring inflammatory markers can aid in assessing disease severity and guiding treatment strategies.